Effect of NO donor sodium nitroprusside on lipopolysaccharide induced acute lung injury in rats.
Nitric oxide (NO) donor-sodium nitroprusside (SNP) mitigates acute lung injury (ALI), but the mechanism of this protection is incompletely known. We investigated the effect of SNP on lipopolysaccharide (LPS)-induced ALI in rats. Forty-eight male Wistar rats were randomly assigned into six groups: the sham-operation group (S group), the LPS instillation group (LPS group), the haemin, a haeme oxygenase-1 (HO-1) inducer, pretreatment group (HM group), the haemin pretreatment plus LPS instillation group (HM+LPS group), the SNP alone and SNP plus LPS treatment groups. Macroscopic and histopathological examinations and immunohistochemistry analysis were performed for the lung specimens 8h after LPS instillation. Intratracheal administration of LPS induced significant expressions of the inducible isoform of NO synthase (iNOS) and HO-1, while both haemin pretreatment and SNP treatment increased the expression of HO-1 and prevented the expression of iNOS. In the LPS group, the wet-dry weight ratio (W/D), bronchoalveolar lavage fluid (BALF) protein, and lung malondialdehyde (MDA) content were significantly higher than those in the sham-operation group, which were reversed by the pretreatment with haemin or administration of SNP. These results suggest that HO-1 plays a protective role against LPS-induced acute lung injury, which may be achieved at least in part, via inactivating the iNOS/NO system that is involved in the pathophysiological process of LPS-induced acute lung injury. The nitric oxide (NO) donor-SNP ameliorates LPS-induced ALI, which may be related to the induction of HO-1 and the subsequent inhibition of iNOS.
Xia
Zhong-yuan
ZY
Anesthesiology Research Laboratory, Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan 430060, PR China.
Wang
Xiao-yuan
XY
Chen
Xiangdong
X
Xia
Zhengyuan
Z
D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D051547:Heme Oxygenase-1 / Q000378:metabolism; D006427:Hemin / Q000627:therapeutic use; D008070:Lipopolysaccharides; D008168:Lung / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D020030:Nitric Oxide Donors / Q000627:therapeutic use*; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D009599:Nitroprusside / Q000627:therapeutic use*; D009929:Organ Size; D010100:Oxygen / Q000097:blood; D010313:Partial Pressure; D011506:Proteins / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012128:Respiratory Distress Syndrome / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*
D008070:Lipopolysaccharides; D020030:Nitric Oxide Donors; D011506:Proteins; D009599:Nitroprusside; D008315:Malondialdehyde; D006427:Hemin; D052247:Nitric Oxide Synthase Type II; D051547:Heme Oxygenase-1; D010100:Oxygen